[24]Indeed, current guidance from the American Society of Clinical Oncology, the European Organization for Research and Treatment of Cancer, the Infectious Disease Society of America, and the National Comprehensive Cancer Network recommend primary prophylaxis when the incidence of febrile neutropenia is expected to be greater than 20%.[25–28] In Uganda, the use of G-CSF to treat or prevent chemotherapy-induced neutropenia is not routine and generally unaffordable. This evidence concerns the gene CSF3 and Decreased total neutrophil count.